Antisense oligonucleotide DGAT-2 inhibitor, ION224, for metabolic dysfunction-associated steatohepatitis (ION224-CS2): results of a 51-week, multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- Journal:
- The Lancet
- Published:
- Affiliations:
- 3
- Authors:
- 8
| Institutions | Authors | Share |
|---|---|---|
| Ionis Pharmaceuticals, United States of America (USA) | 0.67 | |
| UC San Diego Health Sciences, United States of America (USA) | 0.17 | |
| Arizona Liver Health, United States of America (USA) | 0.17 |